Abstract
INTRODUCTION
The number of aortic valve procedures is increasing in the aging populations of the Western world. Bioprostheses are the mainstay of aortic valve replacement (AVR) in elderly persons, but their use is increasing in younger patients as well [1] . Although the impact on prognosis is still unclear, there is general agreement that prosthesis haemodynamics determines clinical success after AVR. Newly designed surgical valves were developed with a strong focus on haemodynamic performance. Sorin's (now LivaNova) Freedom Solo V R (FS) bioprosthesis is the latest evolution of pericardial stentless valves with a simplified, faster implantation procedure compared with other stentless valves [2] [3] [4] . Stentless prostheses are favoured precisely for their haemodynamic profile and their ability to mimic the native aortic valve. However, concerns have been raised about the risk of long-term structural valve deterioration (SVD) [5, 6] . St. Jude's (now Abbott) Trifecta V R (TF) is a new stented bioprosthesis with externally mounted pericardial leaflets that allow for theoretical optimization of effective orifice area (EOA). Its design has been proposed to compete with stentless prostheses while retaining the advantages of the stented frame. These 2 bovine pericardial bioprostheses have been widely adopted at most centres and we aimed to compare TF with FS, the most †Presented at the 31st Annual Meeting of the European Association for CardioThoracic Surgery, Vienna, Austria, 7-10 October 2017 and at the 4D Visions Congress of the Portuguese Society of Cardiothoracic and Vascular Surgery, Albufeira, Portugal, 24-26 November 2017. ‡The first two authors contributed equally to this study.
recently available models of their respective counterparts. The main goal of the present study was to compare the mid-term clinical outcomes and short-term haemodynamic performances of stentless FS and stented TF bioprostheses.
MATERIALS AND METHODS

Study design and patients
In this longitudinal cohort study with prospectively collected data, we included consecutive patients undergoing AVR performed with either the FS or the TF (implanted at our centre since 2009 and 2011, respectively, until June 2016) at the Cardiothoracic Surgery Department of Centro Hospitalar São João, Porto, Portugal. Both cases of isolated AVR and combined procedures were included. Group allocation was the decision of the surgical team. Patients crossing-over at reoperation were excluded, as were those who had Bentall and aortic root enlargement procedures and a 29-mm TF prosthesis, because there was no counterpart for them in the FS group.
Data sources
Data were collected from the databases and clinical records of the Cardiothoracic Surgery Department. National records were consulted for clinical, echocardiographic follow-up and survival data. Data were censored on March 2017. This study was approved by the Centro Hospitalar São João ethics committee and was conducted in accordance with the 1964 Helsinki declaration and its later amendments. Informed consent was waived due to the retrospective nature of the study, and all data were anonymized for analysis.
Surgical technique
Bioprostheses were implanted in a supra-annular position under standard cardiopulmonary bypass (CPB) and hypothermic cardioplegic arrest with either transverse or longitudinal aortotomy. TF valves were sutured using interrupted polyester sutures, and FS valves were implanted using running polypropylene sutures. Postoperative vitamin K antagonists were prescribed routinely for 3 months in patients younger than 80 years, unless contraindicated.
Outcomes
Immediate postoperative events recorded were de novo atrial fibrillation (AF), permanent pacemaker implantation, renal impairment (duplication of serum creatinine values or need for renal replacement therapy), prolonged mechanical ventilation (>24 h), severe thrombocytopenia (platelet count <30 Â 10 9 /l), stroke, length of stay, early chest re-exploration for bleeding or cardiac tamponade and death. Prosthesis-related complications recorded were nonstructural valve dysfunction, SVD and endocarditis. SVD during follow-up was defined according to the valve academic research consortium-2 (VARC-2) criteria: mean transprosthetic gradient (MTG) > _20 mmHg, EOA < _0.9-1.1 cm 2 and/or Doppler velocity index < _0.35 m/s, and/or moderate or severe prosthetic valve regurgitation [7] . Postoperative evaluation including clinical observation and transthoracic echocardiography was done at our centre's outpatient clinic or, occasionally, at other centres. [8] . LV mass was estimated using Devereux's formula and indexed for body surface area. A composite outcome defined as SVD or prosthesis endocarditis was assessed [7] . Echocardiographic data for prosthesis haemodynamics and LV mass regression were obtained independently from non-fatal follow-up outcomes, and losses to follow-up were distinct for the various outcomes (Fig. 1) .
Statistical analysis
Categorical and continuous variables are presented as count (valid percentage, excluding missing values) and mean (standard deviation) or median (interquartile range) according to their distribution. Incidence rates (hazard rates) are expressed as events per 100 person-years. Normality was assessed by the ShapiroWilk test. An unadjusted comparison between groups was carried out for preoperative characteristics, intraoperative findings and postoperative data. To account for measured confounding, we then performed a non-parsimonious 1:1 nearest-neighbour propensity score (PS) matching without replacement (calliper of 0.02) based on logistic regression including 21 clinically relevant preoperative independent covariates, regardless of differences between groups. The PS model was run on a complete case analysis framework due to the absence of missing data. For the remaining variables and outcomes, after auditing and double checking, missing data were found for 20 variables, and only 3 of these had missing values >2% (maximum 6%). Covariate balance was assessed by standardized bias. The Student's t-test or the Mann-Whitney test was used for continuous variables and the v 2 or the Fisher's exact test for categorical variables. The Bonferroni adjustment was used to correct for multiple testing. KaplanMeier survival analysis was used to evaluate all-cause mortality. For analysis of composite outcome, cumulative incidence function was modelled based on Fine and Gray's proportional subdistribution hazards model considering death as a competing event. Because time to postoperative echocardiography differed between groups, the effect on LV mass index and LVEDD was estimated by applying a PS-adjusted mixed effects model, including the respective preoperative and postoperative values as the within-subject factor, group as the between-subject factor and time-group interactions. A P-value <0.05 was considered significant. Statistical analyses were run on Stata version 14.1 (StataCorp, College Station, TX, USA).
RESULTS
Sample characteristics
A study flowchart is outlined in Fig. 1 . From a total of 954 patients retrieved from our database, 32 were excluded. Sample characteristics for the remaining patients of the TF (n = 525) and the FS groups (n = 397) are presented in Table 1 (PS covariates) and Table 2 (other relevant variables), respectively. In the TF group, male gender was more prevalent as was active smoking and the Canadian Cardiovascular Society (CCS) Class III/IV, whereas the FS group showed a higher prevalence of AF. There was a non-significant trend for higher European System for Cardiac Operative Risk Evaluation II (EuroSCORE II) in the TF compared with the FS group (mean EuroSCORE II was 5.1 vs 4.3, respectively). Bioprostheses were implanted under various clinical scenarios with minor differences between groups. Patients in the FS and TF groups did not differ in LV dysfunction, aortic disease pathophysiology or aetiology, but both concomitant tricuspid valve intervention and AF ablation were performed more frequently in the FS group. Mean CPB and aortic cross-clamp times were similar between the groups. The 23-mm diameter was the most frequently implanted size for both prostheses (Fig. 2) . After PS matching (329 pairs), groups were well balanced for all variables included in the PS model, as appraised by absolute standardized bias <10% (Table 1) . From intraoperative findings, only concomitant AF ablation as a combined procedure remained statistically different between the groups (Table 2) .
Early postoperative outcomes
In the unmatched sample, TF showed a higher 30-day mortality rate and more postoperative complications such as need for inotropes or intra-aortic balloon pump, prolonged mechanical ventilation and stroke. Cause of death was cardiac in 3 and 20 patients and infectious in 3 and 8 patients of the FS and TF groups, respectively. One patient in the TF group died of uncontrolled bleeding. Nevertheless, and despite the trend for more deaths, only prolonged mechanical ventilation remained statistically more frequent after matching (Table 3 ). The FS group showed a higher incidence of severe thrombocytopenia, though it did not translate into increased rate of reoperation. Hospital length of stay and worsening kidney function were very similar between the groups, as were other early postoperative outcomes (Table 3) . One patient in each group was reoperated due to sternal wound complications/mediastinitis; 1 patient in the TF group needed early redo AVR due to stent distortion and 3 other patients in the TF group underwent urgent coronary artery bypass surgery due to coronary ostial obstruction.
Prosthesis haemodynamics and ventricular mass regression
During follow-up, 855 transthoracic echocardiography examinations were performed: 488 in the TF group and 367 in the FS group. Echocardiographic data were missing for 10% of patients due either to death (64%) or to loss to follow-up. The percentage lost to follow-up did not differ between the groups. Time to postoperative echocardiography differed between the FS and TF groups [141 (106-202) vs 121 (91-163) days, P < 0.001]. The TF group showed lower MTG and higher EOA (Fig. 2) . Nevertheless, there was no difference in the incidence of PPM: severe PPM was observed in 2 patients with the FS and in 5 patients with the TF (Table 3) . We found no statistically significant interaction between group and prosthesis size. Despite the differences in haemodynamic performance of the prostheses, reverse remodelling was comparable in both groups. The PS-adjusted model showed that LV mass index and LVEDD decreased to a similar extent at follow-up in the FS and TF groups (Fig. 3) . Of note, LVEDD was higher in the TF group. 
Survival and late clinical outcomes
Median follow-up time was 2.4 (1.4-3.7) and 4.0 (2.2-6.0) years in the TF and FS groups, respectively (P < 0.001), and maximum follow-up time was 5.8 and 7.9 years in the TF and FS groups. Death rates and reoperation status were available for all patients. Overall freedom from death at 6 years was 80% in the TF and 82% in the FS group, respectively. No difference was found in time to all-cause mortality (hazard ratio = 1.04, 95% confidence interval 0.69-1.56) in the matched sample (Fig. 4A ). Follow-up data for the combined outcome of SVD and endocarditis were missing for 6% of patients, but in 88% of these due to death. Losses to follow-up were below 1% in both groups regardless of matching. In the matched sample, the cumulative incidence at 6 years for the composite outcome was 6% and 4% in patients with the FS and TF, respectively, and the corresponding incidence rates were 1.3/100 and 0.7/100 person-years. No differences were found in time to composite outcome (subdistribution hazard ratio = 0.54, 95% confidence interval 0.21-1.39) in the matched sample (Fig. 4B) . The stacked cumulative incidence for death or the composite outcome showed that all-cause mortality was the dominant outcome (Fig. 4C) . No differences were found in the incidence of endocarditis, but SVD was more common in patients with the FS (only before PS matching, Table 3 ). Most importantly, there were 9 cases with predominant stenotic SVD in the FS and none in the TF group. Ten patients with the FS and 2 with the TF were reoperated due to SVD or endocarditis. Most patients underwent reintervention due to prosthetic endocarditis, whereas SVD was responsible for redo surgery in 3 patients with the FS and 1 patient with the TF. A higher rate of paravalvular leak was found in the TF (9 cases, 1.7%) versus the FS (1 case, 0.3%) group (P = 0.003).
DISCUSSION
We found an excellent haemodynamic profile of the stentless FS and the stented TF pericardial bioprostheses with a slight advantage for the TF but with similar LV mass regression. SVD, endocarditis rates and all-cause mortality rates were similar between the groups. Haemodynamic performance of surgical aortic valves is of paramount importance. PPM carries a worse prognosis [8, 9] , and small aortic prostheses with a residual gradient impair LV mass regression, which is predictive of poorer survival and more heart failure readmissions [9, 10] . Classical surgical bioprostheses show a high incidence of severe PPM, reaching almost one-third of the patients in some reports [9] . However, different valve designs might have a substantial impact on these parameters, and a relatively large dispersion of postoperative MTG can be found in the literature. In our cohort, we could demonstrate that an excellent haemodynamic profile can be obtained with newer bioprostheses designed specifically with this goal. Both the FS and TF bioprostheses have been shown previously to outperform classical pericardial valves, namely the Perimount Magna [10, 11] . But to our knowledge, only 1 small cohort study focusing on immediate/short-term outcomes has previously compared these 2 bioprostheses [12] . Our EOA and MTG results for the TF and FS are similar to those previously published [6, 13] . Interestingly, in our study, the stented design showed a small but significant haemodynamic advantage, even after adjustment for the PS and stratification for prosthesis size. Nevertheless, the clinical significance of this haemodynamic superiority does not seem to be relevant because no differences were found in LV mass regression, PPM, combined outcome of SVD and endocarditis or survival. These results bring into question the role of a stentless design in achieving optimal haemodynamics.
We found a higher incidence of immediate postoperative complications in unmatched cases with TF compared with FS, including death and stroke, which may be partly explained by the trend towards higher surgical risk, as assessed by the EuroSCORE II. Methodological issues inherent in the study design may additionally explain this finding. However, we might speculate that other unmeasured factors may also play a role: severe root and annular calcification is a relative contraindication to FS; additionally, stentless valves are considered to be technically more demanding and therefore more likely to be implanted by experienced surgeons. Because stentless FS implantation is more complex and time consuming [11] , one would anticipate that the FS would have a lower number of combined procedures and extended periods of CPB compared with the TF. Yet, we found trends for precisely the opposite: a higher number of combined procedures with very similar CPB/aortic cross-clamp times.
Except for the above-mentioned exclusion criteria, our analysis was carried out in an all-comers sample, reflecting our centre's current surgical practice. Both prostheses were readily available to the surgical teams in diversified clinical scenarios, namely reoperations, multiple procedures and bicuspid aortic valves. Under realworld surgical practice settings, both prostheses performed well. Although our results show more than 5 years of follow-up with a reasonable number of at-risk patients (>200 at 4 years), future studies should address long-term durability. Older models of biological aortic valves, despite their questionable haemodynamics, have performed remarkably in this regard [14, 15] . Our follow-up data confirm a usually overlooked detail of post-AVR patients: the cumulative incidence of death is considerably higher than the cumulative incidence of SVD, endocarditis or reoperation [14, 15] . The competing risk of death is an important hurdle to non-fatal valve-related event analysis. We tried to address this issue by modelling the cumulative incidence function as accounting for the competing risk of death [16] . Although the low number of events precludes a definite conclusion, we found a trend towards an increased rate of SVD, mostly stenotic, in the FS group, which challenges the anticipated mechanism of stentless valve failure [5] . Two independent reports [6, 17] have shown that failure of the FS is mainly due to stenosis, and concerns have been raised about the risk of early SVD [18] . Unfortunately, the definition of SVD is not consistent between studies, and it should be noted that the anticipated mode of failure of stentless bioprostheses has not been frequently verified [5] . In our series, we defined SVD according to the VARC-2 criteria, which tend to overestimate prosthesis stenosis in non-reoperated patients [7, 17] . The TF bioprosthesis on the other hand was introduced more recently, so long-term results are scarce [13, 19, 20] . Questions have been raised about the risk of early SVD of TF valves [18, 21] . Our series reports 1 case of severe aortic regurgitation caused by stent distortion and 3 cases of need for urgent coronary artery bypass surgery due to coronary ostial obstruction in the early postoperative period. Others have speculated about the possible long-term impact of minor stent deformations that are not detected intraoperatively [18] . As may happen with the FS, if the implantation technique is not done correctly, the longterm durability of the TF might also be affected.
Limitations
PS analysis does not address unmeasured confounding. Followup time was limited and longer for the FS valve, which was available for surgical implantation earlier in our department, a bias which can only be partly controlled for. Time to postoperative transthoracic echocardiography was longer with the TF for logistic reasons (growing number of surgical cases and longer waiting time until follow-up echocardiography). This issue was partly considered by our statistical model. Many determinants of LV mass regression were not controlled for, namely postoperative systemic hypertension and AF. Therefore, our conclusions on mass regression deserve a word of caution. Power analysis for our sample size estimates shows an ability to detect 10% differences in survival on follow-up between groups (for 2-tailed significance set at 0.05) with a power above 80%. However, the low event rates of the remaining outcomes may preclude our ability to detect small differences. 
CONCLUSION
In conclusion, TF and FS bioprostheses are good alternatives for AVR. Both achieve excellent haemodynamic performance and comparable degrees of LV mass regression. However, the acid test for these and other biological valves is necessarily durability, which will only be possible to determine with long-term studies.
